{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:54:25Z","timestamp":1792886065316,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med."],"abstract":"<jats:p>Natural human monoclonal antibodies obtained from sentinel lymph nodes of cancer patients identify cell surface vimentin. One of these vimentin-reactive antibodies, pritumumab, has been used to treat brain cancer patients. This review summarizes data on mAbs reactive with cell surface vimentin and their origin from lymph nodes of cancer patients.<\/jats:p>","DOI":"10.3389\/fmmed.2025.1552323","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T01:38:04Z","timestamp":1740015484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cell surface vimentin: a natural human immune response target for immunotherapy"],"prefix":"10.3389","volume":"5","author":[{"given":"Mark C.","family":"Glassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/HAB-180348","article-title":"Antibody drug conjugates: progress, pitfalls, and promises","volume":"27","author":"Anubhab","year":"2019","journal-title":"Hum. Antibodies"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1224352","DOI":"10.3389\/fimmu.2023.1224352","article-title":"Vimentin: from a cytoskeletal protein to a critical modulator of immune response and a target for infection","volume":"14","author":"Arrindell","year":"2023","journal-title":"Front. Immunol."},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-8958-4_19","article-title":"A binding potency assay for pritumumab and ecto-domain vimentin","volume-title":"Methods in molecular biology; vol 1904; human monoclonal antibodies; methods and protocols","author":"Babic","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1242\/jcs.043042","article-title":"Recruitment of vimentin to the cell surface by beta3 integrin and plectin mediates adhesion strength","volume":"122","author":"Bhattacharya","year":"2009","journal-title":"J. Cell Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5114\/pg.2014.47502","article-title":"The aberrant overexpression of vimentin is linked to a more aggressive status in tumours of the gastrointestinal tract","volume":"10","author":"Brzozowa","year":"2015","journal-title":"Prz. Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"vdae166","DOI":"10.1093\/noajnl\/vdae166","article-title":"A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases","volume":"6","author":"Carrillo","year":"2024","journal-title":"Neuro-Oncology Adv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF02071523","article-title":"Management of the regional lymph nodes in patients with cutaneous malignant melanoma","volume":"16","author":"Cochran","year":"1992","journal-title":"World J. Surg."},{"key":"B8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biosystems.2004.05.033","article-title":"Cluster and information entropy analysis of the complementarity determining regions in antibodies","volume":"77","author":"Culler","year":"2004","journal-title":"BioSystems"},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/978-1-59745-323-3_2","article-title":"Recombinant monoclonal antibodies","volume":"378","author":"Donzeau","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"R522","DOI":"10.1016\/j.cub.2021.04.011","article-title":"Intermediate filaments","volume":"31","author":"Dutour-Provenzano","year":"2021","journal-title":"Curr. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/excr.2000.4881","article-title":"Crypto-1-induced increase in vimentin expression is associated with enhanced migration of human caski cervical carcinoma cells","volume":"257","author":"Ebert","year":"2000","journal-title":"Exp. Cell Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1242\/jcs.113.13.2455","article-title":"Impaired wound healing in embryonic and adult mice lacking vimentin","volume":"113","author":"Eckes","year":"2000","journal-title":"J. Cell Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1242\/jcs.111.13.1897","article-title":"Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts","volume":"111","author":"Eckes","year":"1998","journal-title":"J. Cell Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4130393","DOI":"10.1074\/jbc.m605452200","article-title":"A direct interaction between actin and vimentin filaments mediated by the tail domain of vimentin","volume":"281","author":"Esue","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Sig Transduct. Target Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1517\/14712598.5.10.1333","article-title":"Requirements for human antibody cocktails for oncology","volume":"5","author":"Glassy","year":"2005","journal-title":"Expert. Opin. Biol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/hab-2007-163-403","article-title":"Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts","volume":"16","author":"Glassy","year":"2007","journal-title":"Hum. Antibod"},{"key":"B19","first-page":"5181","article-title":"Immortalization of human lymphocytes from a tumor involved lymph node","volume":"47","author":"Glassy","year":"1987","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/HAB-200427","article-title":"Unconventional immunotherapy with an unconventional target","author":"Glassy","year":"2020","journal-title":"Hum. Antibod"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-62703-586-6_2","article-title":"Technical and ethical limitations in making human monoclonal antibodies (an overview)","volume":"1060","author":"Glassy","year":"2013","journal-title":"Methods Mol. Biol. Clifton, N.J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/HAB-2009-0209","article-title":"Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab","volume":"18","author":"Glassy","year":"2009","journal-title":"Hum. Antibod"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1073\/pnas.80.20.6327","article-title":"UC 729-6, a human lymphoblastoid B cell line useful for generating antibody secreting human-human hybridomas","volume":"80","author":"Glassy","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B24","first-page":"853","article-title":"A novel drug discovery program utilizing the human immune response","volume":"2","author":"Glassy","year":"1993","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1517\/13543784.3.10.1057","article-title":"Pharming the human lymph node","volume":"3","author":"Glassy","year":"1994","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"B26","article-title":"Oligoclonal and polyclonal antibodies in immunotherapy","volume-title":"Handbook of immunotherapy","author":"Gupta","year":"2014"},{"key":"B27","first-page":"318","article-title":"Use of the Gpex\u00ae system to increase production of pritumumab in a CHO cell line","volume":"98","author":"Gupta","year":"2013","journal-title":"J. Bioprocess Technol. Phot."},{"key":"B28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/HAB-2001-10204","article-title":"Determination of the antigen\/epitope that is recognized by human monoclonal antibody CLN-IgG","volume":"10","author":"Hagiwara","year":"2001","journal-title":"Hum. Antibod"},{"key":"B29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-024-03043-6","article-title":"Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer","volume":"43","author":"Heming","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.yexcr.2007.03.040","article-title":"Novel functions of vimentin in cell adhesion, migration, and signaling","volume":"313","author":"Ivaska","year":"2007","journal-title":"Exp. Cell Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial\u2013mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1165\/rcmb.2013-0314TR","article-title":"The role of vimentin intermediate filaments in the progression of lung cancer","volume":"50","author":"Kidd","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B33","first-page":"153","article-title":"Nakajima, Human monoclonal antibody SK-1 immunotargeting for rectal carcinoma","volume":"14","author":"Koda","year":"","journal-title":"N. Intl. J. Immunother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/hab-1990-1104","article-title":"In vitro immunization for the production of human monoclonal antibody","volume":"1","author":"Koda","year":"1990","journal-title":"Hum. Antibod. Hybridomas"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/archsurg.1990.01410240073015","article-title":"Generation of human monoclonal antibodies against colon cancer","volume":"125","author":"Koda","year":"1990","journal-title":"Arch. Surg."},{"key":"B36","first-page":"621","article-title":"Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK1","volume":"21","author":"Koda","year":"2001","journal-title":"Anticancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.1998.677","article-title":"A human natural antibody to adenocarcinoma that inhibits tumour cell migration","volume":"78","author":"Koda","year":"","journal-title":"Brit. J. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e61983","DOI":"10.7759\/cureus.61983","article-title":"A comprehensive review of monoclonal antibodies in modern medicine: tracing the evolution of a revolutionary therapeutic approach","volume":"16","author":"Kothari","year":"2024","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/hab-2003-12402","article-title":"Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma","volume":"12","author":"Kotlan","year":"2003","journal-title":"Hum. Antibod"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.4049\/jimmunol.175.4.2278","article-title":"Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes","volume":"175","author":"Kotlan","year":"2005","journal-title":"J. Immunol."},{"key":"B41","first-page":"9","article-title":"Characteristics of tumor gangliosides revealed by B cells infiltrating human breast carcinomas","volume":"15","author":"Kotlan","year":"2006","journal-title":"Hum. Antibod"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.xphs.2022.05.014","article-title":"It is never too late for a cocktail - development and analytical characterization of fixed-dose antibody combinations","volume":"111","author":"Krieg","year":"2022","journal-title":"J. Pharmeceut. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jcmm.12850","article-title":"Vimentin, colon cancer progression and resistance to butyrate and other HDACis","volume":"20","author":"Lazarova","year":"2016","journal-title":"J. Cell Mol. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bpj.2014.04.050","article-title":"Vimentin enhances cell elastic behavior and protects against compressive stress","volume":"107","author":"Mendez","year":"2014","journal-title":"Biophys. J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1096\/fj.09-151639","article-title":"Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition","volume":"24","author":"Mendez","year":"2010","journal-title":"FASEB J."},{"key":"B46","article-title":"Preclinical characterization of CHO-derived pritumumab targeting ecto-domain vimentin in xenograft models and primate safety","author":"Modi","year":"2024","journal-title":"Sci. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch. Surg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3233\/hab-1999-9102","article-title":"Co-expression of tumor antigens and their modulation by pleiotrophic modifiers enhance targeting of human monoclonal antibodies to pancreatic carcinoma","volume":"9","author":"Mukerjee","year":"1999","journal-title":"Hum. Antibodies"},{"key":"B49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/hyb.1998.17.133","article-title":"Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells","volume":"17","author":"Mukerjee","year":"1998","journal-title":"Hybridoma"},{"key":"B50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1089\/hyb.1997.16.427","article-title":"Cloning and expression of the human tumor specific antibody GM4","volume":"16","author":"Nasoff","year":"1997","journal-title":"Hybridoma"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1387\/ijdb.072410mn","article-title":"Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives","volume":"53","author":"Nieto","year":"2009","journal-title":"Int. J. Dev. Biol."},{"key":"B52","volume-title":"Philadelphia","author":"Node Biopsy","year":"1982"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/1097-0142(19911201)68:11<2378::aid-cncr2820681108>3.0.co;2-2","article-title":"Potential of human lymph node cells for antitumor activity mediated by interferon gamma","volume":"68","author":"Okadome","year":"1991","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"883178","DOI":"10.3389\/fimmu.2022.883178","article-title":"Evasion of NK cell immune surveillance via the vimentin-mediated cytoskeleton remodeling","volume":"13","author":"Peng","year":"2022","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell Mol. Life Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188985","article-title":"Extracellular vimentin as a versatile immune suppressive protein in cancer. September 2023 Biochim Biophys Acta","author":"Tabatabaee","year":"2024","journal-title":"Rev. Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.4049\/jimmunol.167.6.3089","article-title":"Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites","volume":"167","author":"Tanigawa","year":"2001","journal-title":"J. Immunol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10154-7","article-title":"Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance","author":"van Loon","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal centers. Ann","volume":"40","author":"Victoria","year":"2022","journal-title":"Rev. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1349-7006.1992.tb02346.x","article-title":"Use of a local immunotherapy as an adjunctive tool for the generation of human monoclonal antibodies from regional lymph nodes of colonic cancer patients","volume":"83","author":"Yagyu","year":"1992","journal-title":"J. Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.prp.2018.07.014","article-title":"Vimentin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis","volume":"214","author":"Yin","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"B63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/cts.12043","article-title":"Clinical significance of vimentin expression and her-2 status in patients with gastric carcinoma","volume":"6","author":"Zhao","year":"2013","journal-title":"Clin. Transl. Sci."}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2025.1552323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T01:38:09Z","timestamp":1740015489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2025.1552323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":63,"alternative-id":["10.3389\/fmmed.2025.1552323"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2025.1552323","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"article-number":"1552323"}}